Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00754923 2019-03-06

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 8 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00454194 2017-03-21

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

110 enrolled 15 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00411671 2016-02-11

BATTLE Program: Sorafenib in Patients With NSCLC

Phase 2 Completed

105 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00726986 2014-11-19

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2 Terminated

18 enrolled 9 charts

Thoracic

Lung Neoplasms

NCT00456716 2010-03-04

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Phase 2 Completed

5 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT00801385 2009-08-25

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Phase 2 Unknown

47 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

BATTLE Program: Sorafenib in Patients With NSCLC

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy